News Join our mailing list to receive our quarterly email newsletter with news, updates and events in bowel management. SUBSCRIBE AllCancerCoeliac DiseaseConstipationIncontinenceIBSInflammatory Bowel DiseasePaediatricsEnhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancerMay 13, 2020Entyvio® (Vedolizumab) receives marketing authorisation for Ulcerative Colitis & Crohn’s DiseaseMay 13, 2020NICE positive FAD recommends STELARA® for ulcerative colitisApril 28, 2020NICE publish COVID-19 rapid guideline for gastrointestinal conditionsApril 23, 2020SMC accepts STELARA® for ulcerative colitis treatment in ScotlandApril 15, 2020Coeliac UK launches appeal to keep support going for thousands with autoimmune diseaseApril 6, 2020AI chatbot partners with pharma to support IBD patients during Covid-19April 6, 2020Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab in Ulcerative Colitis or Crohn’s DiseaseMarch 6, 2020NICE updates guidance for colorectal cancerFebruary 24, 2020FDA accepts regulatory submission of sNDA for LYNPARZA® (olaparib) in prostate cancerJanuary 29, 2020FDA approves DIFICID® (fidaxomicin) to treat clostridium difficile associated diarrhoea in childrenJanuary 29, 2020AstraZeneca & Daiichi Sankyo’s Phase II trial DESTINY-Gastric01 reaches primary end pointJanuary 29, 20204 1234567 5
Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancerMay 13, 2020
Entyvio® (Vedolizumab) receives marketing authorisation for Ulcerative Colitis & Crohn’s DiseaseMay 13, 2020
Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab in Ulcerative Colitis or Crohn’s DiseaseMarch 6, 2020
FDA accepts regulatory submission of sNDA for LYNPARZA® (olaparib) in prostate cancerJanuary 29, 2020
FDA approves DIFICID® (fidaxomicin) to treat clostridium difficile associated diarrhoea in childrenJanuary 29, 2020
AstraZeneca & Daiichi Sankyo’s Phase II trial DESTINY-Gastric01 reaches primary end pointJanuary 29, 2020
